Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.

Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Magliulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omedè P, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Foà R, Massaia M, Boccadoro M, Coscia M.

Haematologica. 2019 Jul 9. pii: haematol.2019.217430. doi: 10.3324/haematol.2019.217430. [Epub ahead of print]

PMID:
31289209
Free Article
2.

Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.

Busato D, Mossenta M, Baboci L, Di Cintio F, Toffoli G, Dal Bo M.

Expert Rev Clin Pharmacol. 2019 May;12(5):453-470. doi: 10.1080/17512433.2019.1598859. Epub 2019 Apr 14. Review.

PMID:
30907177
3.

KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival.

Vendramini E, Bomben R, Pozzo F, Benedetti D, Bittolo T, Rossi FM, Dal Bo M, Rabe KG, Pozzato G, Zaja F, Chiarenza A, Di Raimondo F, Braggio E, Parikh SA, Kay NE, Shanafelt TD, Del Poeta G, Gattei V, Zucchetto A.

Leukemia. 2019 Mar 14. doi: 10.1038/s41375-019-0444-6. [Epub ahead of print] No abstract available.

PMID:
30872781
4.

A B-cell receptor-related gene signature predicts response to ibrutinib treatmeant in mantle cell lymphoma cell lines.

D'Agaro T, Zucchetto A, Vit F, Bittolo T, Tissino E, Rossi FM, Degan M, Zaja F, Bulian P, Dal Bo M, Ferrero S, Ladetto M, Zamò A, Gattei V, Bomben R.

Haematologica. 2019 Feb 28. pii: haematol.2018.212811. doi: 10.3324/haematol.2018.212811. [Epub ahead of print]

5.

Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.

Raponi S, Del Giudice I, Ilari C, Cafforio L, Messina M, Cappelli LV, Bonina S, Piciocchi A, Marinelli M, Peragine N, Mariglia P, Mauro FR, Rigolin GM, Rossi F, Bomben R, Dal Bo M, Del Poeta G, Diop F, Favini C, Rossi D, Gaidano G, Cuneo A, Gattei V, Guarini A, Foá R.

Br J Haematol. 2019 Apr;185(1):156-159. doi: 10.1111/bjh.15405. Epub 2018 May 22. No abstract available.

PMID:
29785734
6.

Expression of the transcribed ultraconserved region 70 and the related long non-coding RNA AC092652.2-202 has prognostic value in Chronic Lymphocytic Leukaemia.

Bomben R, Roisman A, D'Agaro T, Castellano G, Baumann T, Delgado J, López-Guillermo A, Zucchetto A, Dal-Bo M, Bravin V, Slavutsky I, Vlasova A, Guigó R, Martin-Subero JI, Chapaprieta V, Beekman R, Martin-García D, Beà S, Salaverria I, Aymerich M, Campo E, Gattei V, Hernández L.

Br J Haematol. 2019 Mar;184(6):1045-1050. doi: 10.1111/bjh.15237. Epub 2018 Apr 24. No abstract available.

PMID:
29687884
7.

A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.

Bomben R, Ferrero S, D'Agaro T, Dal Bo M, Re A, Evangelista A, Carella AM, Zamò A, Vitolo U, Omedè P, Rusconi C, Arcaini L, Rigacci L, Luminari S, Piccin A, Liu D, Wiestner A, Gaidano G, Cortelazzo S, Ladetto M, Gattei V.

Haematologica. 2018 May;103(5):849-856. doi: 10.3324/haematol.2017.184325. Epub 2018 Feb 22.

8.

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.

Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A.

J Exp Med. 2018 Feb 5;215(2):681-697. doi: 10.1084/jem.20171288. Epub 2018 Jan 4.

9.

NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.

Benedetti D, Tissino E, Pozzo F, Bittolo T, Caldana C, Perini C, Martorelli D, Bravin V, D'Agaro T, Rossi FM, Bomben R, Santinelli E, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Poeta G, Rossi D, Gaidano G, Dal Bo M, Gattei V, Zucchetto A.

Leukemia. 2018 Mar;32(3):654-662. doi: 10.1038/leu.2017.296. Epub 2017 Sep 22.

PMID:
28935990
10.

NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.

D'Agaro T, Bittolo T, Bravin V, Dal Bo M, Pozzo F, Bulian P, Rossi FM, Zucchetto A, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Bomben R.

Br J Haematol. 2018 Aug;182(4):597-602. doi: 10.1111/bjh.14843. Epub 2017 Jul 12. No abstract available.

PMID:
28699643
11.

Mutations in the 3' untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia.

Bittolo T, Pozzo F, Bomben R, D'Agaro T, Bravin V, Bulian P, Rossi FM, Zucchetto A, Degan M, Macor P, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M.

Haematologica. 2017 Aug;102(8):e305-e309. doi: 10.3324/haematol.2016.162594. Epub 2017 May 26. No abstract available.

12.

NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.

Pozzo F, Bittolo T, Vendramini E, Bomben R, Bulian P, Rossi FM, Zucchetto A, Tissino E, Degan M, D'Arena G, Di Raimondo F, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M.

Leukemia. 2017 Nov;31(11):2407-2415. doi: 10.1038/leu.2017.90. Epub 2017 Mar 21.

PMID:
28321119
13.

Low-dose radiotherapy in diffuse large B-cell lymphoma.

Furlan C, Canzonieri V, Spina M, Michieli M, Ermacora A, Maestro R, Piccinin S, Bomben R, Dal Bo M, Trovo M, Gattei V, Tirelli U, Franchin G, Bulian P.

Hematol Oncol. 2017 Dec;35(4):472-479. doi: 10.1002/hon.2368. Epub 2016 Oct 25.

PMID:
27781290
14.

Solute lean Ti-Nb-Fe alloys: An exploratory study.

Salvador CAF, Dal Bó MR, Costa FH, Taipina MO, Lopes ESN, Caram R.

J Mech Behav Biomed Mater. 2017 Jan;65:761-769. doi: 10.1016/j.jmbbm.2016.09.024. Epub 2016 Sep 19.

PMID:
27768940
15.

Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia.

Dal Bo M, Tissino E, Benedetti D, Caldana C, Bomben R, Poeta GD, Gaidano G, Rossi FM, Bulian P, Zucchetto A, Gattei V.

Curr Cancer Drug Targets. 2016;16(8):659-668. Review.

PMID:
27514846
16.

Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.

Del Poeta G, Postorino M, Pupo L, Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Mariotti B, Iannella E, Maurillo L, Venditti A, Gattei V, de Fabritiis P, Cantonetti M, Amadori S.

Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954. Review.

PMID:
27252989
17.

CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.

Dal Bo M, Bulian P, Bomben R, Zucchetto A, Rossi FM, Pozzo F, Tissino E, Benedetti D, Bittolo T, Nanni P, Cattarossi I, Zaina E, Chivilò H, Degan M, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Principe MI, Del Poeta G, Rossi D, Gaidano G, Gattei V.

Leukemia. 2016 Oct;30(10):2011-2018. doi: 10.1038/leu.2016.88. Epub 2016 Apr 25.

PMID:
27109509
18.

Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.

Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Rossi FM, Zucchetto A, Rossi D, Bomben R, Maurillo L, Cefalo M, De Santis G, Venditti A, Gaidano G, Amadori S, de Fabritiis P, Gattei V, Del Poeta G.

Haematologica. 2016 Jan;101(1):77-85. doi: 10.3324/haematol.2015.131854. Epub 2015 Nov 12.

19.

The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential.

Dal Bo M, Bomben R, Hernández L, Gattei V.

Oncotarget. 2015 Aug 14;6(23):19381-92. Review.

20.

Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?

Benedetti D, Tissino E, Caldana C, Dal Bo M, Bomben R, Marconi D, Ganghammer S, Zaja F, Pozzato G, Di Raimondo F, Hartmann TN, Del Poeta G, VanMeter A, Zucchetto A, Espina V, Liotta L, Gattei V.

Leukemia. 2016 Feb;30(2):513-7. doi: 10.1038/leu.2015.149. Epub 2015 Jun 19. No abstract available.

PMID:
26183532
21.

NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.

Pozzo F, Bittolo T, Arruga F, Bulian P, Macor P, Tissino E, Gizdic B, Rossi FM, Bomben R, Zucchetto A, Benedetti D, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Deaglio S, Gattei V, Dal Bo M.

Leukemia. 2016 Jan;30(1):182-9. doi: 10.1038/leu.2015.182. Epub 2015 Jul 13.

PMID:
26165233
22.

The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.

Dal Bo M, D'Agaro T, Gobessi S, Zucchetto A, Dereani S, Rossi D, Zaja F, Pozzato G, Di Raimondo F, Gaidano G, Laurenti L, Del Poeta G, Efremov DG, Gattei V, Bomben R.

Oncotarget. 2015 Aug 7;6(22):19102-17.

23.

Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.

Famà R, Bomben R, Rasi S, Dal Bo M, Ciardullo C, Monti S, Rossi F, D'Agaro T, Zucchetto A, Gattei V, Gaidano G, Rossi D.

Blood. 2014 Dec 11;124(25):3831-3. doi: 10.1182/blood-2014-08-592725. No abstract available.

24.

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia.

Dereani S, Macor P, D'Agaro T, Mezzaroba N, Dal-Bo M, Capolla S, Zucchetto A, Tissino E, Del Poeta G, Zorzet S, Gattei V, Bomben R.

J Hematol Oncol. 2014 Oct 23;7:79. doi: 10.1186/s13045-014-0079-z.

25.

The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma.

Piva R, Deaglio S, Famà R, Buonincontri R, Scarfò I, Bruscaggin A, Mereu E, Serra S, Spina V, Brusa D, Garaffo G, Monti S, Dal Bo M, Marasca R, Arcaini L, Neri A, Gattei V, Paulli M, Tiacci E, Bertoni F, Pileri SA, Foà R, Inghirami G, Gaidano G, Rossi D.

Leukemia. 2015 Feb;29(2):503-7. doi: 10.1038/leu.2014.294. Epub 2014 Oct 6. No abstract available.

PMID:
25283840
26.

Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d.

Dal Bo M, Tissino E, Benedetti D, Caldana C, Bomben R, Del Poeta G, Gaidano G, Rossi FM, Zucchetto A, Gattei V.

Semin Hematol. 2014 Jul;51(3):168-76. doi: 10.1053/j.seminhematol.2014.05.002. Epub 2014 May 15. Review.

PMID:
25048781
27.

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.

Pozzo F, Dal Bo M, Peragine N, Bomben R, Zucchetto A, Rossi F, Degan M, Rossi D, Chiarenza A, Grossi A, Di Raimondo F, Zaja F, Pozzato G, Secchiero P, Gaidano G, Del Poeta G, Zauli G, Fo À R, Guarini A, Gattei V.

J Hematol Oncol. 2013 Nov 5;6:83. doi: 10.1186/1756-8722-6-83.

28.

CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34(+) hemopoietic progenitors cells.

Rossi FM, Zucchetto A, Tissino E, Dal Bo M, Bomben R, Caldana C, Pozzo F, Del Poeta G, Rossi D, Gaidano G, Gattei V.

Leukemia. 2014 Mar;28(3):705-8. doi: 10.1038/leu.2013.331. Epub 2013 Nov 8. No abstract available.

PMID:
24202404
29.

CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism.

Zucchetto A, Caldana C, Benedetti D, Tissino E, Rossi FM, Hutterer E, Pozzo F, Bomben R, Dal Bo M, D'Arena G, Zaja F, Pozzato G, Di Raimondo F, Hartmann TN, Rossi D, Gaidano G, Del Poeta G, Gattei V.

Blood. 2013 Nov 7;122(19):3317-21. doi: 10.1182/blood-2013-06-507335. Epub 2013 Sep 25.

30.

Depressive Symptoms and Associated Factors among People Living with HIV/AIDS.

Dal-Bó MJ, Manoel AL, Filho AO, Silva BQ, Cardoso YS, Cortez J, Tramujas L, Silva RM.

J Int Assoc Provid AIDS Care. 2015 Mar-Apr;14(2):136-40. doi: 10.1177/2325957413494829. Epub 2013 Jul 19.

PMID:
23873218
31.

Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.

Rossi D, Spina V, Bomben R, Rasi S, Dal-Bo M, Bruscaggin A, Rossi FM, Monti S, Degan M, Ciardullo C, Serra R, Zucchetto A, Nomdedeu J, Bulian P, Grossi A, Zaja F, Pozzato G, Laurenti L, Efremov DG, Di-Raimondo F, Marasca R, Forconi F, Del Poeta G, Gaidano G, Gattei V.

Blood. 2013 Jun 13;121(24):4902-5. doi: 10.1182/blood-2013-02-486209. Epub 2013 May 1.

32.

ARHGDIA, a mutant TP53-associated Rho GDP dissociation inhibitor, is over-expressed in gene expression profiles of TP53 disrupted chronic lymphocytic leukaemia cells.

Dal Bo M, Pozzo F, Bomben R, Degan M, Marconi D, Zucchetto A, Rossi D, Pozzato G, Zauli G, Gaidano G, Del Poeta G, Gattei V.

Br J Haematol. 2013 May;161(4):596-9. doi: 10.1111/bjh.12258. Epub 2013 Feb 14. No abstract available.

PMID:
23406297
33.

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.

Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C, Deambrogi C, Khiabanian H, Serra R, Bertoni F, Forconi F, Laurenti L, Marasca R, Dal-Bo M, Rossi FM, Bulian P, Nomdedeu J, Del Poeta G, Gattei V, Pasqualucci L, Rabadan R, Foà R, Dalla-Favera R, Gaidano G.

Blood. 2013 Feb 21;121(8):1403-12. doi: 10.1182/blood-2012-09-458265. Epub 2012 Dec 13.

34.

Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia.

Del Poeta G, Dal Bo M, Del Principe MI, Pozzo F, Rossi FM, Zucchetto A, Bomben R, Degan M, Rasi S, Rossi D, Bulian P, Gaidano G, Amadori S, Gattei V.

Br J Haematol. 2013 Feb;160(3):415-8. doi: 10.1111/bjh.12128. Epub 2012 Nov 20. No abstract available.

PMID:
23167503
35.

Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy.

Dal Bo M, Bomben R, Zucchetto A, Del Poeta G, Gaidano G, Deaglio S, Efremov DG, Gattei V.

Curr Pharm Des. 2012;18(23):3323-34. Review.

PMID:
22591383
36.

The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes.

Bomben R, Gobessi S, Dal Bo M, Volinia S, Marconi D, Tissino E, Benedetti D, Zucchetto A, Rossi D, Gaidano G, Del Poeta G, Laurenti L, Efremov DG, Gattei V.

Leukemia. 2012 Jul;26(7):1584-93. doi: 10.1038/leu.2012.44. Epub 2012 Feb 20.

PMID:
22343732
37.

The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells.

Zucchetto A, Vaisitti T, Benedetti D, Tissino E, Bertagnolo V, Rossi D, Bomben R, Dal Bo M, Del Principe MI, Gorgone A, Pozzato G, Gaidano G, Del Poeta G, Malavasi F, Deaglio S, Gattei V.

Leukemia. 2012 Jun;26(6):1301-12. doi: 10.1038/leu.2011.369. Epub 2012 Jan 6.

PMID:
22289918
38.

CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.

Del Poeta G, Del Principe MI, Zucchetto A, Luciano F, Buccisano F, Rossi FM, Bruno A, Biagi A, Bulian P, Maurillo L, Neri B, Bomben R, Simotti C, Coletta AM, Dal Bo M, de Fabritiis P, Venditti A, Gattei V, Amadori S.

Haematologica. 2012 Feb;97(2):279-87. doi: 10.3324/haematol.2011.052829. Epub 2011 Oct 11.

39.

13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia.

Dal Bo M, Rossi FM, Rossi D, Deambrogi C, Bertoni F, Del Giudice I, Palumbo G, Nanni M, Rinaldi A, Kwee I, Tissino E, Corradini G, Gozzetti A, Cencini E, Ladetto M, Coletta AM, Luciano F, Bulian P, Pozzato G, Laurenti L, Forconi F, Di Raimondo F, Marasca R, Del Poeta G, Gaidano G, Foà R, Guarini A, Gattei V.

Genes Chromosomes Cancer. 2011 Aug;50(8):633-43. doi: 10.1002/gcc.20885. Epub 2011 May 11.

PMID:
21563234
40.

B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage.

Dal-Bo M, Del Giudice I, Bomben R, Capello D, Bertoni F, Forconi F, Laurenti L, Rossi D, Zucchetto A, Pozzato G, Marasca R, Efremov DG, Guarini A, Del Poeta G, Foà R, Gaidano G, Gattei V.

Br J Haematol. 2011 Apr;153(1):3-14. doi: 10.1111/j.1365-2141.2010.08440.x. Epub 2011 Feb 8. Review.

PMID:
21303354
41.

Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort.

Bilous N, Bomben R, Dal Bo M, Capello D, Forconi F, Laurenti L, Bertoni F, Efremov DG, Marasca R, Del Poeta G, Martina Z, Kryachouk I, Dyagil I, Gaidano G, Chumak A, Gattei V, Abramenko I.

Leuk Lymphoma. 2010 May;51(5):822-38. doi: 10.3109/10428191003646002.

PMID:
20233059
42.

Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells.

Rossi FM, Del Principe MI, Rossi D, Irno Consalvo M, Luciano F, Zucchetto A, Bulian P, Bomben R, Dal Bo M, Fangazio M, Benedetti D, Degan M, Gaidano G, Del Poeta G, Gattei V.

J Transl Med. 2010 Mar 8;8:23. doi: 10.1186/1479-5876-8-23.

43.

Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features.

Bomben R, Dal-Bo M, Benedetti D, Capello D, Forconi F, Marconi D, Bertoni F, Maffei R, Laurenti L, Rossi D, Del Principe MI, Luciano F, Sozzi E, Cattarossi I, Zucchetto A, Rossi FM, Bulian P, Zucca E, Nicoloso MS, Degan M, Marasca R, Efremov DG, Del Poeta G, Gaidano G, Gattei V.

Clin Cancer Res. 2010 Jan 15;16(2):620-8. doi: 10.1158/1078-0432.CCR-09-1638. Epub 2010 Jan 12.

44.

IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia.

Bomben R, Dal Bo M, Capello D, Forconi F, Bertoni F, Maffei R, Laurenti L, Rossi D, Zucca E, Degan M, Marasca R, Efremov DG, Del Poeta G, Gaidano G, Gattei V.

Br J Haematol. 2010 Apr;149(2):299-302. doi: 10.1111/j.1365-2141.2009.08046.x. Epub 2009 Jan 7. No abstract available.

PMID:
20064162
45.

The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia.

Secchiero P, di Iasio MG, Melloni E, Voltan R, Celeghini C, Tiribelli M, Dal Bo M, Gattei V, Zauli G.

Leukemia. 2010 Feb;24(2):480-3. doi: 10.1038/leu.2009.215. Epub 2009 Oct 22. No abstract available.

PMID:
19847196
46.

Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance.

Dal-Bo M, Bertoni F, Forconi F, Zucchetto A, Bomben R, Marasca R, Deaglio S, Laurenti L, Efremov DG, Gaidano G, Del Poeta G, Gattei V.

J Transl Med. 2009 Aug 28;7:76. doi: 10.1186/1479-5876-7-76. Review.

47.

Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity.

Zauli G, di Iasio MG, Secchiero P, Dal Bo M, Marconi D, Bomben R, Del Poeta G, Gattei V.

Curr Cancer Drug Targets. 2009 Jun;9(4):510-8.

PMID:
19519319
48.

CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.

Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal Bo M, Marconi D, Bossi F, Lorenzon D, Degan M, Rossi FM, Rossi D, Bulian P, Franco V, Del Poeta G, Deaglio S, Gaidano G, Tedesco F, Malavasi F, Gattei V.

Cancer Res. 2009 May 1;69(9):4001-9. doi: 10.1158/0008-5472.CAN-08-4173. Epub 2009 Apr 21.

49.

Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study.

Bomben R, Dal Bo M, Capello D, Forconi F, Maffei R, Laurenti L, Rossi D, Del Principe MI, Zucchetto A, Bertoni F, Rossi FM, Bulian P, Cattarossi I, Ilariucci F, Sozzi E, Spina V, Zucca E, Degan M, Lauria F, Del Poeta G, Efremov DG, Marasca R, Gaidano G, Gattei V.

Br J Haematol. 2009 Feb;144(4):492-506. doi: 10.1111/j.1365-2141.2008.07469.x. Epub 2008 Nov 19.

PMID:
19036101
50.

Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia.

Gattei V, Bulian P, Del Principe MI, Zucchetto A, Maurillo L, Buccisano F, Bomben R, Dal-Bo M, Luciano F, Rossi FM, Degan M, Amadori S, Del Poeta G.

Blood. 2008 Jan 15;111(2):865-73. Epub 2007 Oct 24.

Supplemental Content

Loading ...
Support Center